Phospholipase A2 Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention

EA Dennis, J Cao, YH Hsu, V Magrioti… - Chemical …, 2011 - ACS Publications
1.1. Discovery of the Phospholipase A2 Superfamily Phospholipases represent one of the
earliest enzyme activities to be identified and studied, and the phospholipase A2 (PLA2) …

[HTML][HTML] Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches

D Nikolic, N Katsiki, G Montalto, ER Isenovic… - Nutrients, 2013 - mdpi.com
Small, dense low density lipoprotein (sdLDL) represents an emerging cardiovascular risk
factor, since these particles can be associated with cardiovascular disease (CVD) …

Lipoprotein-associated phospholipase A (2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.

A Thompson, P Gao, L Orfei, S Watson… - Lancet (London …, 2010 - europepmc.org
Background Lipoprotein-associated phospholipase A (2)(Lp-PLA (2)), an inflammatory
enzyme expressed in atherosclerotic plaques, is a therapeutic target being assessed in trials …

[HTML][HTML] Regulation and deregulation of cholesterol homeostasis: The liver as a metabolic “power station”

L Trapani, M Segatto, V Pallottini - World journal of hepatology, 2012 - ncbi.nlm.nih.gov
Cholesterol plays several structural and metabolic roles that are vital for human biology. It
spreads along the entire plasma membrane of the cell, modulating fluidity and concentrating …

Lipoprotein-Associated Phospholipase A2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 …

M O'Donoghue, DA Morrow, MS Sabatine, SA Murphy… - Circulation, 2006 - Am Heart Assoc
Background—Lipoprotein-associated phospholipase A2 (Lp-PLA2) is associated with the
risk of cardiovascular (CV) events in population-based studies. The prognostic value of Lp …

The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart …

ER Mohler, CM Ballantyne, MH Davidson… - Journal of the American …, 2008 - jacc.org
Objectives: This study examined the effects of darapladib, a selective lipoprotein-associated
phospholipase A2 (Lp-PLA2) inhibitor, on biomarkers of cardiovascular (CV) risk …

Oxidized phospholipids and lipoprotein‐associated phospholipase A2 (Lp‐PLA2) in atherosclerotic cardiovascular disease: An update

D Pantazi, C Tellis, AD Tselepis - Biofactors, 2022 - Wiley Online Library
Inflammation and oxidative stress conditions lead to a variety of oxidative modifications of
lipoprotein phospholipids implicated in the occurrence and development of atherosclerotic …

Τhe role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma

CC Tellis, AD Tselepis - Biochimica et Biophysica Acta (BBA)-Molecular …, 2009 - Elsevier
Platelet-activating factor (PAF) acetylhydrolase exhibits a Ca2+-independent phospholipase
A2 activity and degrades PAF as well as oxidized phospholipids (oxPL). Such phospholipids …

Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects

M Persson, B Hedblad, JJ Nelson… - … , and vascular biology, 2007 - Am Heart Assoc
Background—To explore potential interrelationships between lipoprotein-associated
phosholipase A2 (Lp-PLA2), the metabolic syndrome (MetS), and incident cardiovascular …

Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass …

MH Davidson, KC Maki, H Bays, R Carter… - Journal of clinical …, 2009 - Elsevier
BACKGROUND: Prescription omega-3-acid ethyl esters (P-OM3) often are used for
hypertriglyceridemic patients receiving statin therapy who have residual increases in …